Annual Report

The report presents 2014 as a year of strategic reshaping, led by GSK's proposed three-part transaction with Novartis to strengthen Vaccines and Consumer Healthcare while divesting marketed Oncology assets. It highlights four new product approvals, strong new-product sales, continued leadership in the Access to Medicine Index, and major malaria and Ebola vaccine milestones. The company also reports responsible-business activity across health access, ethical conduct, people, and environmental impacts, including lower operational Scope 1 and 2 emissions and reduced water use. Governance disclosures describe Board-level Corporate Responsibility Committee oversight and extensive action following the China compliance investigation.